Business
FDA throws wet blanket on Mesoblast’s treatment for bone marrow transplant condition – Business News Australia
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
The Melbourne-based company has sought US regulatory approval for its stem cell-based product remestemcel-L in treating graft versus host disease (GvHD) – a potentially life-threatening condition that some people experience after receiving a bone marrow tran…
-
Business22 hours agoLeading brokers name 3 ASX shares to buy today 15 September 2025
-
Noosa News22 hours agoTrio charged over backyard ‘veterinary drug’ euthanasia operation
-
Noosa News21 hours agoUpdate 1: Assault and robbery, Morayfield
-
Business23 hours agoExpert tips this ASX ETF to keep outperforming the ASX 200